Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BROTHER Study of pembrolizumab with carbon-ion chemoradiotherapy for locally advanced cervical adenocarcinoma
jRCTs031240651Recruiting
- Sponsor
- MSD
- Start
- Jun 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab and cisplatin in Cervical Cancer (CC), cervical adenocarcinoma and Adenosquamous Cervical Cancer (ASC), sponsored by MSD. Primary endpoint: 2-year progression-free survival. Started Jun 2025; status: recruiting.
02
Drugs
pembrolizumabcisplatin
03
Conditions
Cervical Cancer (CC)cervical adenocarcinomaAdenosquamous Cervical Cancer (ASC)
Beyond the preview
Go deeper on jRCTs031240651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240651.